Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10055, Taiwan.
Department of Obstetrics & Gynecology, E-da Cancer Hospital, Kaohsiung 82445, Taiwan.
Epigenomics. 2018 Nov;10(11):1397-1413. doi: 10.2217/epi-2018-0035. Epub 2018 Oct 16.
To investigate the CDH1, DLEC1 and SFRP5 gene methylation panel for advanced epithelial ovarian carcinoma (EOC).
MATERIALS & METHODS: One hundred and seventy-seven advanced EOC specimens were evaluated by methylation-specific PCR. We also used The Cancer Genome Atlas dataset to evaluate the panel.
The presence of two or more methylated genes was significant in recurrence (hazard ratio [HR]: 1.91 [1.33-2.76]; p = 0.002) and death (HR: 1.96 [1.26-3.06]; p = 0.006) in our cohort. In The Cancer Genome Atlas dataset, the presence of two or three methylated genes was significant in death (HR: 1.59 [1.15-2.18]; p = 0.0047) and close to the significance level in recurrence (HR: 1.37 [0.99-1.88]; p = 0.058).
The CDH1, DLEC1 and SFRP5 methylation panel is a potential prognostic biomarker for advanced EOC.
研究 CDH1、DLEC1 和 SFRP5 基因甲基化panel 对晚期上皮性卵巢癌（EOC）的作用。
采用甲基化特异性 PCR 对 177 例晚期 EOC 标本进行评估。我们还使用癌症基因组图谱数据集来评估该 panel。
在我们的队列中，存在两个或更多甲基化基因与复发（风险比 [HR]：1.91 [1.33-2.76]；p=0.002）和死亡（HR：1.96 [1.26-3.06]；p=0.006）显著相关。在癌症基因组图谱数据集中，存在两个或三个甲基化基因与死亡（HR：1.59 [1.15-2.18]；p=0.0047）显著相关，与复发接近显著水平（HR：1.37 [0.99-1.88]；p=0.058）。
CDH1、DLEC1 和 SFRP5 甲基化 panel 是晚期 EOC 的一个有潜力的预后生物标志物。
